The end of HIV: Still a very long way to go, but progress continues
Publication Date
November 30, 2017
PLOS Medicine
Steven G. Deeks, Sharon R. Lewin & Linda-Gail Bekker
Publisher URL
Loading … Spinner

Mendeley | Further Information

{"title"=>"The end of HIV: Still a very long way to go, but progress continues", "authors"=>[{"first_name"=>"Steven G.", "last_name"=>"Deeks", "scopus_author_id"=>"7006700221"}, {"first_name"=>"Sharon R.", "last_name"=>"Lewin", "scopus_author_id"=>"15737239300"}, {"first_name"=>"Linda Gail", "last_name"=>"Bekker", "scopus_author_id"=>"7003924915"}], "year"=>2017, "source"=>"PLoS Medicine", "identifiers"=>{"sgr"=>"85036572233", "pui"=>"619520629", "doi"=>"10.1371/journal.pmed.1002466", "scopus"=>"2-s2.0-85036572233", "issn"=>"15491676", "isbn"=>"1111111111"}, "id"=>"a212cf54-f813-33dc-af53-2d0dc4c71a39", "abstract"=>"Let's End It is the theme of this year's World AIDS Day, which falls on December 1. In the spirit of the event, PLOS Medicine is devoting this special issue to a discussion on advances in HIV prevention, treatment, and cure. Here, we describe many of the remaining barriers in ending the epidemic and highlight a number of accompanying studies that provide paths for-ward for overcoming some of these challenges. An estimated 75 million people have acquired HIV infection since the first reports of infec-tion in the 1970s. Over 35 million people have died. With the advent of combination antiretro-viral therapy (ART) in 1996, the life expectancy of HIV-infected adults in both high-and low-income countries now approaches that of the general population but only in people who start therapy early in the disease process, who take therapy on a daily basis, and who have life-long access to drugs and monitoring of antiviral effects. The remarkably successful and ongoing global effort to provide treatment means that 20.9 million of the estimated 36.7 million people living with HIV globally are now receiving therapy [1]. ART not only improves health but it makes a person noninfectious; HIV-infected mothers on effective ART rarely transmit HIV to their infants, and HIV-infected adults on effective ART have been shown to not transmit the virus to their sexual partners. The significance of these achievements cannot be overstated: in the past 3 decades, global biomedical and public health programs not only discovered how HIV causes disease and developed effective strategies to prevent and treat the infection, but also built a global public health response that is unprecedented in its scale and effectiveness. ART is the mainstay of treatment for people with HIV infection, and a crucial component of UNAIDS's global aims to achieve, by 2020, high proportions (90%) of people, respectively, tested for HIV infection, receiving ART, and with viral suppression (the so-called 90-90-90 ini-tiative) [2]. Despite massive international efforts to achieve this goal, many challenges remain, particularly as many of the key affected populations are highly stigmatized and marginalized. In this issue of PLOS Medicine, various experts address aspects of the challenges facing infants [3], children and adolescents [4], female sex workers [5–7], transgender women [8], men who have sex with men (MSM), and people who inject drugs [9]. In a Perspective on these issues, Wafaa El-Sadr and colleagues discuss the important topic of differentiated service delivery by which process interventions are combined and blended as appropriate for individual populations and settings [10]. As an example, Margaret McNairy and colleagues report on a cluster-randomized trial done in Swaziland [11] testing a combina-tion intervention including point-of-care CD4 testing, prompt initiation of ART, and support-ive components intended to improve adherence. The trial's results show substantial benefits in the trial's primary endpoint of linkage to and retention in care at 1 year, indicating the", "link"=>"", "reader_count"=>8, "reader_count_by_academic_status"=>{"Unspecified"=>1, "Researcher"=>2, "Student > Master"=>1, "Student > Bachelor"=>1, "Professor"=>1, "Lecturer"=>1, "Student > Ph. D. Student"=>1}, "reader_count_by_user_role"=>{"Unspecified"=>1, "Researcher"=>2, "Student > Master"=>1, "Student > Bachelor"=>1, "Professor"=>1, "Lecturer"=>1, "Student > Ph. D. Student"=>1}, "reader_count_by_subject_area"=>{"Unspecified"=>2, "Agricultural and Biological Sciences"=>2, "Medicine and Dentistry"=>3, "Biochemistry, Genetics and Molecular Biology"=>1}, "reader_count_by_subdiscipline"=>{"Medicine and Dentistry"=>{"Medicine and Dentistry"=>3}, "Agricultural and Biological Sciences"=>{"Agricultural and Biological Sciences"=>2}, "Biochemistry, Genetics and Molecular Biology"=>{"Biochemistry, Genetics and Molecular Biology"=>1}, "Unspecified"=>{"Unspecified"=>2}}, "group_count"=>0}

Scopus | Further Information

{"@_fa"=>"true", "link"=>[{"@_fa"=>"true", "@ref"=>"self", "@href"=>""}, {"@_fa"=>"true", "@ref"=>"author-affiliation", "@href"=>",affiliation"}, {"@_fa"=>"true", "@ref"=>"scopus", "@href"=>""}, {"@_fa"=>"true", "@ref"=>"scopus-citedby", "@href"=>""}], "prism:url"=>"", "dc:identifier"=>"SCOPUS_ID:85036572233", "eid"=>"2-s2.0-85036572233", "dc:title"=>"The end of HIV: Still a very long way to go, but progress continues", "dc:creator"=>"Deeks S.", "prism:publicationName"=>"PLoS Medicine", "prism:issn"=>"15491277", "prism:eIssn"=>"15491676", "prism:volume"=>"14", "prism:issueIdentifier"=>"11", "prism:pageRange"=>nil, "prism:coverDate"=>"2017-11-01", "prism:coverDisplayDate"=>"November 2017", "prism:doi"=>"10.1371/journal.pmed.1002466", "citedby-count"=>"0", "affiliation"=>[{"@_fa"=>"true", "affilname"=>"University of California, San Francisco", "affiliation-city"=>"San Francisco", "affiliation-country"=>"United States"}], "pubmed-id"=>"29190733", "prism:aggregationType"=>"Journal", "subtype"=>"ed", "subtypeDescription"=>"Editorial", "article-number"=>"e1002466", "source-id"=>"144840"}



  • {"month"=>"11", "year"=>"2017", "pdf_views"=>"38", "xml_views"=>"31", "html_views"=>"614"}
  • {"month"=>"12", "year"=>"2017", "pdf_views"=>"333", "xml_views"=>"1483", "html_views"=>"6307"}
  • {"month"=>"1", "year"=>"2018", "pdf_views"=>"56", "xml_views"=>"217", "html_views"=>"1561"}
  • {"month"=>"2", "year"=>"2018", "pdf_views"=>"32", "xml_views"=>"3", "html_views"=>"99"}

PMC Usage Stats

  • {"unique-ip"=>"19", "full-text"=>"20", "pdf"=>"9", "abstract"=>"0", "scanned-summary"=>"0", "scanned-page-browse"=>"0", "figure"=>"0", "supp-data"=>"0", "cited-by"=>"0", "year"=>"2017", "month"=>"12"}
  • {"unique-ip"=>"54", "full-text"=>"53", "pdf"=>"27", "abstract"=>"0", "scanned-summary"=>"0", "scanned-page-browse"=>"0", "figure"=>"0", "supp-data"=>"0", "cited-by"=>"0", "year"=>"2018", "month"=>"1"}
Loading … Spinner
There are currently no alerts